Extended indication Asthma in adults inadequately controlled with dual steroid/beta agonist therapy
Therapeutic value Possible equal value
Total cost 1,516,200.00
Registration phase Registration application pending

Product

Active substance Fluticasone furoate / umeclidinium / vilanterol
Domain Lung diseases
Reason of inclusion Indication extension
Main indication Asthma
Extended indication Asthma in adults inadequately controlled with dual steroid/beta agonist therapy
Proprietary name Trelegy Ellipta
Manufacturer GSK
Mechanism of action LABA / LAMA / ICS
Route of administration Inhalation
Therapeutical formulation Inhalation powder
Budgetting framework Extramural (GVS)
Additional remarks glucocorticoid agonist + long-acting beta2 agonist + muscarinic acetylcholine antagonist

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date January 2020
Expected Registration April 2021
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Current treatment options Aparte toediening van de bestanddelen
Therapeutic value Possible equal value
Substantiation De mogelijke meerwaarde zit vooral in het gebruiksgemak niet zo zeer in de werking. Het is niet mogelijk concentraties van individuele bestanddelen aan te passen.
Duration of treatment continuous
Frequency of administration 1 times a day
References NCT02924688

Expected patient volume per year

Patient volume

2,166

Market share is generally not included unless otherwise stated.

References Volksgezondheidenzorg.info; Weersink et al. Ned Tijdschr Geneeskd. 2013;157:A6232; expertopinie
Additional remarks In 2015 waren er naar schatting 613.500 personen met astma 5-10% van de astmapopulatie is moeilijk instelbaar (30.000-60.000). Momenteel gebruiken 6.500 patiënten losse triple-combinaties. Het zal de in de toekomst de markt moeten delen met Trimbow en Enerzair Breezhaler. Als er uitgegaan wordt van een gelijke verdeling zal dit betekenen dat er 2.166 patiënten in aanmerking zullen komen voor deze behandeling.

Expected cost per patient per year

Cost 700.00
References G-standaard
Additional remarks 12 verpakkingen van 30 doseringen kosten €703,80.

Potential total cost per year

Total cost

1,516,200.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension No
References clincialtrials.gov
Additional remarks Geen andere indicaties onderzocht in fase 3 van het klinisch onderzoek.

Other information

There is currently no futher information available.